Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: A decade of the PREDICT-HD study

Frontiers in Aging Neuroscience

Volumn 6, Issue APR, 2014, Pages

  Paulsen, Jane S ^a,b   Long, Jeffrey D ^a,b   Johnson, Hans J ^a,b   Aylward, Elizabeth H ^c   Ross, Christopher A ^d   Williams, Janet K ^e   Nance, Martha A ^f   Erwin, Cheryl J ^g   Westervelt, Holly J ^h   Harrington, Deborah L ^i,j   Bockholt, H Jeremy ^k   Zhang, Ying ^l   McCusker, Elizabeth A ^m,r   Chiu, Edmond M ⁿ   Panegyres, Peter K ^o,z   Cross, Stephen ^b   Ryan, Patricia ^b   Epping, Eric A ^b   Preston, Joy ⁿ   Goh, Anita ⁿ   Antonopoulos, Stephanie ⁿ   Loi, Samantha ⁿ   Raymond, Lynn ^p   Decolongon, Joji ^p   Fan, Mannie ^p   Coleman, Allison ^p   Mallone, William M ^q   Suter, Greg ^q   Varvaris, Mark ^d   Yoritomo, Nadine ^d   Griffith, Jane ^r   Loy, Clement ^r   Gunn, David ^r   Guttman, Mark ^s   Sheinberg, Alanna ^s   Law, Albie ^s   Quaid, Kimberly ^t   Wesson, Melissa ^t   Wojcieszek, Joanne ^t   Perlmutter, Joel ^u   Barton, Stacey ^u   Smith, Shineeka ^u   Barker, Roger A ^v   Mason, Sarah ^v   Guzman, Natalie Valle ^v   Perlman, Susan ^w   Clemente, Brian ^w   Jones, Randi ^x   Wood Siverio, Cathy ^x   Factor, Stewart A ^x   Samii, Ali ^y   Macaraeg, Alma ^y   Lee, Joseph ^z   Tedesco, Maria ^z   Maxwell, Brenton ^z   Kumar, Rajeev ^aa   Erickson, Diane ^aa   Nickels, Breanna ^aa   Marshall, Frederick ^ab   Chesire, Amy ^ab   Wodarski, Mary ^ab   Hickey, Charlyne ^ab   Geschwind, Michael D ^ac   Sha, Sharon ^ac   Satris, Gabriela ^ac   Ahmed, Anwar ^ad   Reece, Christine ^ad   Bura, Alex ^ad   Mourany, Lyla ^ad   Pillai, Jagan ^ad   Mazzoni, Pietro ^ae   Marder, Karen ^ae   Wasserman, Paula ^ae   Craufurd, David ^af   Bek, Judith ^af   Howard, Elizabeth ^af   Warner, Tom ^ag   Burrows, Maggie ^ag   Orth, Michael ^ah   Süßmuth, Sigurd ^ah   Barth, Katrin ^ah   Trautmann, Sonja ^ah   Schwenk, Daniela ^ah   Eschenbach, Carolin ^ah   Wheelock, Vicki ^ai   Kjer, Lisa ^ai   Martin, Amanda ^ai   Farias, Sarah ^ai   Miedzybrodzka, Zosia ^aj   Rae, Daniela ^aj   D'Alessandro, Mariella ^aj   Suchowersky, Oksana ⁿ   Chua, Phyllis ⁿ   Komiti, Angela ⁿ   Rosas, Diana ^ak   Rosser, Anne ^al   Price, Kathy ^al   Hunt, Sarah ^al   Jankovic, Joseph ^am   Ondo, William ^am   Martin, Wayne ^an   King, Pamela ^an   Wieler, Marguerite ^an   Sran, Satwinder ^an   de Yébenes, Justo Garcia ^ao   Dubinsky, Richard ^ap   more..

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF IOWA COLLEGE OF NURSING   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^h BROWN UNIVERSITY   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^k Advanced Biomedical Informatics Group LLC   (United States)

^l UNIVERSITY OF ALASKA FAIRBANKS   (United States)

^m UNIVERSITY OF SYDNEY   (Australia)

ⁿ UNIVERSITY OF MELBOURNE   (Australia)

^o Neurodegenerative Disorders Research Pty Ltd   (Australia)

^p UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^q Hereditary Neurological Disease Centre   (United States)

^r WESTMEAD HOSPITAL   (Australia)

^s UNIVERSITY OF TORONTO   (Canada)

^t INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^u WASHINGTON UNIVERSITY   (United States)

^v UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^w UCLA MEDICAL CENTER   (United States)

^x EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^y UNIVERSITY OF WASHINGTON   (United States)

^z Graylands Selby Lemnos and Special Care Health Services   (Australia)

^aa Washington University ^*  (United States)

^ab UNIVERSITY OF ROCHESTER   (United States)

^ac UNIVERSITY OF CALIFORNIA   (United States)

^ad LERNER RESEARCH INSTITUTE   (United States)

^ae NewYork Presbyterian Hospital   (United States)

^af UNIVERSITY OF MANCHESTER   (United Kingdom)

^ag NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^ah UNIVERSITY OF ULM   (Germany)

^ai UNIVERSITY OF CALIFORNIA   (United States)

^aj Clinical Genetics Centre   (United Kingdom)

^ak MASSACHUSETTS GENERAL HOSPITAL   (United States)

^al CARDIFF UNIVERSITY   (United Kingdom)

^am BAYLOR COLLEGE OF MEDICINE   (United States)

^an UNIVERSITY OF ALBERTA   (Canada)

^ao HOSPITAL RAMÓN Y CAJAL   (Spain)

^ap UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

more..

Author keywords

Clinical trials; Huntington disease; Natural history; Neurodegenerative disorders; Outcome measures; PREDICT HD; Premanifest

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ARTICLE; BRADYKINESIA; BRAIN SIZE; CEREBROSPINAL FLUID; CHOREA; CONTROLLED STUDY; DISEASE COURSE; EVERYDAY COGNITION RATING SCALE; FEASIBILITY STUDY; FEMALE; FUNCTIONAL STATUS; GENETIC SCREENING; HIPPOCAMPUS; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBSERVATIONAL STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PUTAMEN; SYMPTOM CHECKLIST 90; THALAMUS; UNIFIED HUNTINGTON DISEASE RATING SCALE;

EID: 84901341459     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00078     Document Type: Article

References (31)

1. Aylward, E. H., Nopoulos, P. C., Ross, C. A., Langbehn, D. R., Pierson, R. K., Mills, J. A., et al. (2011). Longitudinal change in regional brain volumes in prodromal Huntington disease. J. Neurol. Neurosurg. Psychiatr. 82, 405-410. doi: 10.1136/jnnp.2010.208264
2. Biglan, K. M., Ross, C. A., Langbehn, D. R., Aylward, E. H., Stout, J. C., Queller, S., et al. (2009). Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov. Disord. 24, 1763-1772. doi:10.1002/mds.22601
3. Czaplinski, A., Haverkamp, L. J., Yen, A. A., Simpson, E. P., Lai, E. C., and Appel, S. H. (2006). The value of database controls in pilot or futility studies in ALS. Neurology 67, 1827-1832. doi:10.1212/01.wnl.0000244415.48221.81
4. Duff, K., Paulsen, J. S., Beglinger, L. J., Langbehn, D. R., Stout, J. C., and PREDICT-HD Investigators of the Huntington Study Group. (2007). Psychiatric symptoms in Huntington's disease before diagnosis: the Predict-HD study. Biol. Psychiatry 62, 1341-1346. doi:10.1016/j.biopsych.2006.11.034
5. Elm, J. J., Goetz, C. G., Ravina, B., Shannon, K., Wooten, G. F., Tanner, C. M., et al. (2005). A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann. Neurol. 57, 197-203. doi:10.1002/ana.20361
6. Hart, E., Middelkoop, H., Jurgens, C. K., Witjes-Ane, M. N., and Roos, R. A. (2011). Seven-year clinical follow-up of premanifest carriers of Huntington's disease. PLoS Curr. 3:RRN1288. doi:10.1371/currents.RRN1288
7. Huntington Study Group. (2006). Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66, 366-372. doi:10.1212/01.wnl.0000198586.85250.13
8. Kirkwood, S. C., Siemers, E., Stout, J. C., Hodes, M. E., Conneally, P. M., Christian, J. C., et al. (1999). Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. Arch. Neurol. 56, 563-568. doi:10.1001/archneur.56.5.563
9. Lemiere, J., Decruyenaere, M., Evers-Kiebooms, G., Vandenbussche, E., and Dom, R. (2002). Longitudinal study evaluating neuropsychological changes in so-called asymptomatic carriers of the Huntington's disease mutation after 1 year. Acta Neurol. Scand. 106, 131-141. doi:10.1034/j.1600-0404.2002.01192.x
10. Lemiere, J., Decruyenaere, M., Evers-Kiebooms, G., Vandenbussche, E., and Dom, R. (2004). Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation - a longitudinal follow-up study. J. Neurol. 251, 935-942. doi:10.1007/s00415-004-0461-9
11. Little, R. J. A., and Rubin, D. B. (2002). Statistical Analysis with Missing Data. New York: Wiley.
12. Majid, D. S., Aron, A. R., Thompson, W., Sheldon, S., Hamza, S., Stoffers, D., et al. (2011). Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation. Mov. Disord. 26, 2544-2551. doi:10.1002/mds.23912
13. Maroof, D. A., Gross, A. L., and Brandt, J. (2011). Modeling longitudinal change in motor and cognitive processing speed in presymptomatic Huntington's disease. J. Clin. Exp. Neuropsychol. 33, 901-909. doi:10.1080/13803395.2011.574606
14. O'Rourke, J. J., Beglinger, L. J., Smith, M. M., Mills, J., Moser, D. J., Rowe, K. C., et al. (2011). The Trail Making Test in prodromal Huntington disease: contributions of disease progression to test performance. J. Clin. Exp. Neuropsychol. 33, 567-579. doi:10.1080/13803395.2010.541228
15. Papp, K. V., Snyder, P. J., Mills, J. A., Duff, K., Westervelt, H. J., Long, J. D., et al. (2013). Measuring executive dysfunction longitudinally and in relation to genetic burden, brain volumetrics, and depression in prodromal Huntington disease. Arch. Clin. Neuropsychol. 28, 156-168. doi:10.1093/arclin/acs105
16. Paulsen, J. S., Hayden, M., Stout, J. C., Langbehn, D. R., Aylward, E., Ross, C. A., et al. (2006). Investigators of the Huntington Study Group preparing for preventive clinical trials: the Predict-HD study. Arch. Neurol. 63, 883-890. doi:10.1001/archneur.63.6.883
17. Paulsen, J. S., Langbehn, D. R., Stout, J. C., Aylward, E., Ross, C. A., Nance, M., et al. (2008). Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J. Neurol. Neurosurg. Psychiatr. 79, 874-880. doi:10.1136/jnnp.2007.128728
18. Paulsen, J. S., Smith, M. M., Long, J. D., PREDICT-HD Investigators and Coordinators of the Huntington Study Group. (2013). Cognitive decline in prodromal Huntington disease: implications for clinical trials. J. Neurol. Neurosurg. Psychiatr. 84, 1233-1239. doi:10.1136/jnnp-2013-305114
19. Paulsen, J. S., Zhao, H., Stout, J. C., Brinkman, R. R., Guttman, M., Ross, C. A., et al. (2001). Clinical markers of early disease in persons near onset of Huntington's disease. Neurology 57, 658-662. doi:10.1212/WNL.57.4.658
20. Penney, J. B. Jr., Vonsattel, J. P., Macdonald, M. E., Gusella, J. F., and Myers, R. H. (1997). CAG repeat number governs the development rate of pathology in Huntington's disease. Ann. Neurol. 41, 689-692. doi:10.1002/ana.410410521
21. Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., et al. (2014). Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat. Rev. Neurol. 10, 204-216. doi:10.1038/nrneurol.2014.24
22. Ross, C. A., and Tabrizi, S. J. (2011). Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83-98. doi:10.1016/S1474-4422(10)70245-3
23. Rowe, K. C., Paulsen, J. S., Langbehn, D. R., Duff, K., Beglinger, L. J., Wang, C., et al. (2010). Self-paced timing detects and tracks change in prodromal Huntington disease. Neuropsychology 24, 435-442. doi:10.1037/a0018905
24. Rupp, J., Blekher, T., Jackson, J., Beristain, X., Marshall, J., Hui, S., et al. (2010). Progression in prediagnostic Huntington disease. J. Neurol. Neurosurg. Psychiatr. 81, 379-384. doi:10.1136/jnnp.2009.176982
25. Snowden, J. S., Craufurd, D., Thompson, J., and Neary, D. (2002). Psychomotor, executive, and memory function in preclinical Huntington's disease. J. Clin. Exp. Neuropsychol. 24, 133-145. doi:10.1076/jcen.24.2.133.998
26. Tabrizi, S. J., Reilmann, R., Roos, R. A., Durr, A., Leavitt, B., Owen, G., et al. (2012). Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 11, 42-53. doi:10.1016/S1474-4422(11)70263-0
27. Tabrizi, S. J., Scahill, R. I., Owen, G., Durr, A., Leavitt, B. R., Roos, R. A., et al. (2013). Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 12, 637-649. doi:10.1016/S1474-4422(13)70088-7
28. The Lancet Neurology. (2012). NeuroNEXT: accelerating drug development in neurology. Lancet Neurol. 11, 119. doi:10.1016/S1474-4422(12)70008-X
29. Verbeke, G., and Molenberghs, G. (2000). Linear Mixed Models for Longitudinal Data. New York: Springer.
30. Zhang, Y., Engelman, J., and Friedlander, R. M. (2009). Allele-specific silencing of mutant Huntington's disease gene. J. Neurochem. 108, 82-90. doi:10.1111/j.1471-4159.2008.05734.x
31. Zhang, Y., Long, J. D., Mills, J. A., Warner, J. H., Lu, W. J., and Paulsen, J. S. (2011). Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156B, 751-763. doi:10.1002/Ajmg.B.31232